EGFR and non-small cell lung carcinoma: The cobas® EGFR Mutation Test v2 was the first PCR-based assay approved by the U.S. Food and Drug Administration (FDA) using circulating cfDNA for the detection of mutations in the epidermal growth factor receptor (EGFR) gene to identify patients with metastatic NSCLC eligible for treatment with the TKI erlotinib [2,39].